Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 15 | 2023 | 306 | 6.140 |
Why?
|
| Thymus Gland | 8 | 2020 | 197 | 2.650 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2018 | 131 | 1.770 |
Why?
|
| Immune Tolerance | 7 | 2021 | 339 | 1.320 |
Why?
|
| Autoantigens | 6 | 2021 | 129 | 1.270 |
Why?
|
| Prostate | 4 | 2016 | 393 | 1.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2021 | 595 | 1.150 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 394 | 1.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2023 | 445 | 1.030 |
Why?
|
| Cell Differentiation | 7 | 2023 | 1522 | 1.030 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 1769 | 1.010 |
Why?
|
| Clone Cells | 7 | 2023 | 214 | 0.910 |
Why?
|
| Neoplasms | 5 | 2018 | 3038 | 0.840 |
Why?
|
| Antigen Presentation | 4 | 2020 | 215 | 0.810 |
Why?
|
| Lymphocyte Activation | 7 | 2021 | 751 | 0.810 |
Why?
|
| Autoimmunity | 3 | 2023 | 168 | 0.780 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2020 | 275 | 0.770 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2017 | 88 | 0.760 |
Why?
|
| Transcription Factors | 4 | 2016 | 1653 | 0.690 |
Why?
|
| Mice | 20 | 2023 | 11757 | 0.690 |
Why?
|
| Dendritic Cells | 3 | 2021 | 449 | 0.690 |
Why?
|
| Lymphopoiesis | 1 | 2020 | 48 | 0.670 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 198 | 0.670 |
Why?
|
| T-Lymphocytes | 4 | 2015 | 1224 | 0.670 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 124 | 0.650 |
Why?
|
| Animals | 25 | 2023 | 27360 | 0.640 |
Why?
|
| Clonal Selection, Antigen-Mediated | 4 | 2020 | 8 | 0.610 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 332 | 0.570 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 2019 | 44 | 0.570 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 3213 | 0.560 |
Why?
|
| Self Tolerance | 1 | 2016 | 25 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 1096 | 0.470 |
Why?
|
| Repressor Proteins | 2 | 2019 | 423 | 0.450 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 189 | 0.400 |
Why?
|
| Mice, Knockout | 6 | 2020 | 1998 | 0.390 |
Why?
|
| Mice, Transgenic | 6 | 2020 | 1574 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 3 | 2017 | 171 | 0.360 |
Why?
|
| Peptides | 3 | 2021 | 648 | 0.330 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2021 | 165 | 0.320 |
Why?
|
| Clonal Deletion | 2 | 2020 | 23 | 0.310 |
Why?
|
| Antigen-Presenting Cells | 3 | 2020 | 141 | 0.290 |
Why?
|
| Antigens | 2 | 2021 | 229 | 0.270 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 171 | 0.270 |
Why?
|
| Histones | 1 | 2008 | 329 | 0.260 |
Why?
|
| Male | 15 | 2021 | 42372 | 0.250 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 1194 | 0.240 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 360 | 0.240 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 98 | 0.220 |
Why?
|
| Ligands | 3 | 2021 | 444 | 0.220 |
Why?
|
| Lymphocyte Depletion | 2 | 2021 | 98 | 0.220 |
Why?
|
| Cell Lineage | 2 | 2016 | 291 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 462 | 0.200 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2023 | 135 | 0.200 |
Why?
|
| Cell Line | 3 | 2021 | 2496 | 0.200 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 15 | 0.200 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 20 | 0.190 |
Why?
|
| Carcinogens | 1 | 2021 | 111 | 0.190 |
Why?
|
| Quinolones | 1 | 2021 | 60 | 0.190 |
Why?
|
| Insecta | 1 | 2021 | 49 | 0.190 |
Why?
|
| Feedback, Physiological | 1 | 2021 | 65 | 0.190 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2062 | 0.180 |
Why?
|
| Cell Movement | 2 | 2016 | 784 | 0.180 |
Why?
|
| CD8 Antigens | 2 | 2019 | 82 | 0.180 |
Why?
|
| Tumor Escape | 2 | 2018 | 51 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 576 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 215 | 0.170 |
Why?
|
| Humans | 17 | 2023 | 89288 | 0.160 |
Why?
|
| Homeostasis | 1 | 2021 | 416 | 0.160 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2019 | 41 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2020 | 163 | 0.160 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 13 | 0.160 |
Why?
|
| Energy Intake | 1 | 1998 | 97 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 168 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 58 | 0.150 |
Why?
|
| Tight Junctions | 1 | 2019 | 150 | 0.150 |
Why?
|
| Epitope Mapping | 1 | 2017 | 16 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2020 | 727 | 0.150 |
Why?
|
| Coronary Disease | 1 | 1998 | 260 | 0.140 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 8 | 0.140 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 16 | 0.140 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 40 | 0.140 |
Why?
|
| Phenotype | 1 | 2023 | 2440 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2017 | 268 | 0.130 |
Why?
|
| B7-1 Antigen | 1 | 2016 | 76 | 0.130 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| B7 Antigens | 1 | 2015 | 5 | 0.130 |
Why?
|
| Major Histocompatibility Complex | 1 | 2014 | 84 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2015 | 342 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 805 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1765 | 0.110 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 47 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2013 | 83 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 275 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 166 | 0.100 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 91 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 890 | 0.100 |
Why?
|
| Haplotypes | 1 | 2013 | 637 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 360 | 0.090 |
Why?
|
| Female | 10 | 2019 | 46157 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 321 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 556 | 0.080 |
Why?
|
| Kinetics | 3 | 2001 | 1528 | 0.080 |
Why?
|
| Hybridomas | 1 | 2008 | 75 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2014 | 691 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2008 | 463 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 100 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2008 | 169 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2012 | 679 | 0.070 |
Why?
|
| Melanoma | 2 | 1999 | 467 | 0.060 |
Why?
|
| HLA-A2 Antigen | 2 | 1999 | 31 | 0.050 |
Why?
|
| Staining and Labeling | 2 | 1999 | 168 | 0.050 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2001 | 9 | 0.050 |
Why?
|
| Paracrine Communication | 1 | 2021 | 32 | 0.050 |
Why?
|
| Membrane Microdomains | 1 | 2021 | 54 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2001 | 24 | 0.050 |
Why?
|
| Half-Life | 1 | 2001 | 97 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2021 | 81 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2002 | 170 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 225 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2021 | 251 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2001 | 311 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 338 | 0.040 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 16 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 43 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 1999 | 32 | 0.040 |
Why?
|
| Diet Surveys | 1 | 1998 | 20 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 181 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 836 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 900 | 0.040 |
Why?
|
| Oligopeptides | 1 | 1999 | 188 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 319 | 0.040 |
Why?
|
| Linear Models | 1 | 1998 | 421 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2002 | 1714 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1088 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 1117 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 3379 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2364 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 988 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 711 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1651 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1072 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 217 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 231 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 308 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 91 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 374 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 66 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 293 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 447 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 98 | 0.030 |
Why?
|
| Risk Factors | 2 | 2002 | 5493 | 0.020 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 14 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 85 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 92 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 374 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 996 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 2623 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 2 | 1999 | 12 | 0.020 |
Why?
|
| MART-1 Antigen | 2 | 1999 | 21 | 0.020 |
Why?
|
| Mutation | 1 | 2001 | 4142 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2014 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 343 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 900 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1242 | 0.020 |
Why?
|
| Adult | 4 | 2013 | 26578 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1999 | 432 | 0.020 |
Why?
|
| Adolescent | 2 | 1998 | 9256 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 1999 | 540 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 2 | 1980 | 37 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 742 | 0.010 |
Why?
|
| Obesity | 2 | 1980 | 971 | 0.010 |
Why?
|
| Triglycerides | 2 | 1980 | 232 | 0.010 |
Why?
|
| Aged | 2 | 2013 | 19143 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 6305 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1999 | 5 | 0.010 |
Why?
|
| Monophenol Monooxygenase | 1 | 1999 | 9 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1999 | 48 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1999 | 38 | 0.010 |
Why?
|
| Body Weight | 1 | 1980 | 452 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1999 | 53 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1999 | 90 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1999 | 38 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1979 | 136 | 0.010 |
Why?
|
| Cell Separation | 1 | 1999 | 198 | 0.010 |
Why?
|
| Cell Communication | 1 | 1999 | 199 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1243 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 502 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 1868 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1012 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1057 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 565 | 0.010 |
Why?
|
| Middle Aged | 3 | 2013 | 25945 | 0.010 |
Why?
|
| Insulin | 1 | 1980 | 1146 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 739 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 4284 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1999 | 1373 | 0.010 |
Why?
|
| Indians, North American | 2 | 1980 | 47 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1999 | 2413 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1980 | 120 | 0.000 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1980 | 68 | 0.000 |
Why?
|
| Mexico | 1 | 1980 | 70 | 0.000 |
Why?
|
| Arizona | 1 | 1979 | 10 | 0.000 |
Why?
|
| Lipoproteins, LDL | 1 | 1979 | 85 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1979 | 97 | 0.000 |
Why?
|
| Glucose Tolerance Test | 1 | 1979 | 227 | 0.000 |
Why?
|
| Cholesterol | 1 | 1980 | 358 | 0.000 |
Why?
|